IMU 0.00% 5.5¢ imugene limited

“We are pleased that there were no safety issues reported from...

  1. 178 Posts.
    lightbulb Created with Sketch. 11
    “We are pleased that there were no safety issues reported from the Cohort Review Committee. The early clinical data is also encouraging, indicating immune activation in vaccinated patients in a manner that is consistent with the vaccine’s postulated mechanism of action.”

    In other words the vaccine is doing exactly as hoped and with only the lowest dose intended to test safety!!!

    Now that all centres are up and running this trial should move quickly especially now HER-vaxx has shown such clinical potential.
 
watchlist Created with Sketch. Add IMU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.